Treatment characteristics (n=130)
| Characteristics | All (n=130) Median (range) |
| Duration of ICI, weeks | 6 (0–145) |
| No. of ICI doses before colitis | 3 (1–34) |
| Duration of steroids, weeks | 10 (0–147) |
| Type of ICI | |
| Adjuvant anti-CTLA-4 | 10 (8%) |
| Combination anti-CTLA-4/PD-1 | 35 (27%) |
| Single agent anti-CTLA-4 | 73 (56%) |
| Single agent anti-PD-1 | 12 (9%) |
| Grade of colitis | |
| I | 5 (4%) |
| II | 7 (5%) |
| III | 98 (75%) |
| IV | 20 (16%) |
| Intravenous steroids at any time | |
| No | 38 (29%) |
| Yes | 92 (71%) |
| Infliximab | |
| No | 78 (60%) |
| Yes | 52 (40%) |
| Flare of colitis | |
| No | 70 (54%) |
| Yes | 60 (46%) |
| No. of patients retreated with anti-PD-1 monotherapy | 49 (38%) |
| Best response (RECIST 1.1) | |
| CR | 12 (9%) |
| PR | 32 (25%) |
| SD | 36 (28%) |
| PD | 50 (38%) |
| PD on/after ICI | |
| No | 47 (36%) |
| Yes | 83 (64%) |
| Death | |
| No | 68 (52%) |
| Yes | 62 (48%) |
CR, complete response; ICI, immune checkpoint inhibition; PD, progressive disease; PR, partial response; SD, stable disease.